Published in DNA Repair (Amst) on May 07, 2007
Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer (2012) 2.52
Extended survival of glioblastoma patients after chemoprotective HSC gene therapy. Sci Transl Med (2012) 1.27
Cytotoxicity associated with artemis overexpression after lentiviral vector-mediated gene transfer. Hum Gene Ther (2010) 0.95
In vivo selection of hematopoietic stem cells transduced at a low multiplicity-of-infection with a foamy viral MGMT(P140K) vector. Exp Hematol (2008) 0.93
Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells. Cancer Res (2008) 0.92
Foamy viral vector integration sites in SCID-repopulating cells after MGMTP140K-mediated in vivo selection. Gene Ther (2015) 0.83
Current progress and challenges in HIV gene therapy. Future Virol (2011) 0.82
Combined preconditioning and in vivo chemoselection with 6-thioguanine alone achieves highly efficient reconstitution of normal hematopoiesis with HPRT-deficient bone marrow. Exp Hematol (2011) 0.80
Genetic modification of mouse bone marrow by lentiviral vector-mediated delivery of hypoxanthine-Guanine phosphoribosyltransferase short hairpin RNA confers chemoprotection against 6-thioguanine cytotoxicity. Transplant Proc (2013) 0.77
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 19.77
A third-generation lentivirus vector with a conditional packaging system. J Virol (1998) 16.07
pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res (1990) 12.75
Transcription start regions in the human genome are favored targets for MLV integration. Science (2003) 12.21
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med (2006) 9.68
Regulation by HIV Rev depends upon recognition of splice sites. Cell (1989) 7.13
Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet (2003) 6.95
Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science (2002) 6.46
Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med (2002) 6.25
Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature (2005) 6.20
Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol (2006) 5.58
Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet (2004) 5.43
Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol (1999) 5.35
Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse. Nature (1984) 5.10
Gene therapy: therapeutic gene causing lymphoma. Nature (2006) 4.89
Conditional site-specific recombination in mammalian cells using a ligand-dependent chimeric Cre recombinase. Proc Natl Acad Sci U S A (1995) 3.94
Demonstration of permanent factor-dependent multipotential (erythroid/neutrophil/basophil) hematopoietic progenitor cell lines. Proc Natl Acad Sci U S A (1983) 3.76
Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci U S A (1986) 3.68
Murine leukemia induced by retroviral gene marking. Science (2002) 3.59
MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer (2004) 3.27
Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood (2006) 3.07
Retrovirus restriction factors. Mol Cell (2004) 2.95
Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum Gene Ther (2005) 2.81
Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat Biotechnol (2004) 2.78
Effective gene therapy with nonintegrating lentiviral vectors. Nat Med (2006) 2.70
Side effects of retroviral gene transfer into hematopoietic stem cells. Blood (2003) 2.35
Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther (2006) 2.34
Retrovirus transfer of a bacterial gene into mouse haematopoietic progenitor cells. Nature (1983) 2.20
Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med (2000) 2.09
Lentiviral vectors for enhanced gene expression in human hematopoietic cells. Mol Ther (2000) 2.01
Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation. Mol Ther (2005) 1.99
Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system. Blood (2004) 1.99
A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc Natl Acad Sci U S A (2000) 1.97
Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J Virol (1995) 1.90
Transient gene expression by nonintegrating lentiviral vectors. Mol Ther (2006) 1.89
Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood (2005) 1.82
Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol Ther (2005) 1.82
AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood (2006) 1.79
Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. Blood (2006) 1.78
Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. Mol Ther (2000) 1.71
Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci U S A (2006) 1.67
High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood (2000) 1.63
Continuous high-titer HIV-1 vector production. Nat Biotechnol (2003) 1.58
Mitotic stability of an episomal vector containing a human scaffold/matrix-attached region is provided by association with nuclear matrix. Nat Cell Biol (2000) 1.53
Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis. Blood (2002) 1.49
Design of 5' untranslated sequences in retroviral vectors developed for medical use. J Virol (1999) 1.48
Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors. Gene Ther (2006) 1.44
Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J Virol (1995) 1.42
Chromatin domain surrounding the human interferon-beta gene as defined by scaffold-attached regions. Biochemistry (1988) 1.42
Efficient transduction of human hematopoietic cells with the human multidrug resistance gene 1 via SV40 pseudovirions. Hum Gene Ther (1998) 1.41
Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors. Mol Ther (2002) 1.41
Performance- and safety-enhanced lentiviral vectors containing the human interferon-beta scaffold attachment region and the chicken beta-globin insulator. Blood (2003) 1.40
Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. Blood (2005) 1.40
Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Ther (2006) 1.39
Lentiviral vectors: regulated gene expression. Mol Ther (2000) 1.39
Multicistronic lentiviral vectors containing the FMDV 2A cleavage factor demonstrate robust expression of encoded genes at limiting MOI. Virol J (2006) 1.38
Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol Ther (2005) 1.38
Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood (2003) 1.34
Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood (2004) 1.34
Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector. Mol Ther (2001) 1.33
Long-term clinical and molecular follow-up of large animals receiving retrovirally transduced stem and progenitor cells: no progression to clonal hematopoiesis or leukemia. Mol Ther (2004) 1.33
RNA 3' readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy. J Virol (2002) 1.32
Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells. Blood (2003) 1.31
Nuclear scaffold/matrix attached region modules linked to a transcription unit are sufficient for replication and maintenance of a mammalian episome. Proc Natl Acad Sci U S A (2004) 1.31
Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. J Clin Invest (2003) 1.27
In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning. J Clin Invest (2003) 1.26
Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow. J Exp Med (1987) 1.24
Highly efficient gene transfer into baboon marrow repopulating cells using GALV-pseudotype oncoretroviral vectors produced by human packaging cells. Blood (2002) 1.24
Self-inactivating retroviral vectors with improved RNA processing. Gene Ther (2004) 1.23
Survival of the fittest: in vivo selection and stem cell gene therapy. Blood (2005) 1.19
Efficient control of gene expression in the hematopoietic system using a single Tet-on inducible lentiviral vector. Mol Ther (2005) 1.17
Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction. Blood (2006) 1.16
Advances in lentiviral vector design for gene-modification of hematopoietic stem cells. Curr Opin Biotechnol (2002) 1.13
A new generation of retroviral producer cells: predictable and stable virus production by Flp-mediated site-specific integration of retroviral vectors. Mol Ther (2006) 1.11
HIV-1-derived lentiviral vectors. Curr Top Microbiol Immunol (2002) 1.10
Increased levels of spliced RNA account for augmented expression from the MFG retroviral vector in hematopoietic cells. Gene Ther (1996) 1.10
Potential oncogene activity of the woodchuck hepatitis post-transcriptional regulatory element (WPRE). Gene Ther (2005) 1.09
Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res (2000) 1.08
Influence of multiplicity of infection and protein stability on retroviral vector-mediated gene expression in hematopoietic cells. Gene Ther (2001) 1.08
Hematopoietic stem cell transduction and amplification in large animal models. Hum Gene Ther (2005) 1.06
In vivo gene transfer into adult stem cells in unconditioned mice by in situ delivery of a lentiviral vector. Mol Ther (2006) 1.05
Packaging of intron-containing genes into retrovirus vectors by alphavirus vectors. Proc Natl Acad Sci U S A (1998) 1.04
Lentiviral gene transfer into primary and secondary NOD/SCID repopulating cells. Blood (2000) 1.03
The current status of gene therapy using hematopoietic stem cells. Curr Opin Pediatr (1995) 1.03
Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. Nat Rev Cancer (2002) 1.01
A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors. Mol Ther (2006) 1.00
Rapid 1-hour transduction of whole bone marrow leads to long-term repopulation of murine recipients with lentivirus-modified hematopoietic stem cells. Gene Ther (2006) 1.00
In vivo selection of human hematopoietic cells in a xenograft model using combined pharmacologic and genetic manipulations. Hum Gene Ther (2003) 0.99
In vivo selection for human and murine hematopoietic cells transduced with a therapeutic MGMT lentiviral vector that inhibits HIV replication. Mol Ther (2004) 0.99
Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy. Hum Gene Ther (1999) 0.97
Construction of retroviral vectors with improved safety, gene expression, and versatility. J Virol (1998) 0.97
Vectors derived from simian immunodeficiency virus (SIV). Biochimie (2002) 0.95
Sustained gene expression in retrovirally transduced, engrafting human hematopoietic stem cells and their lympho-myeloid progeny. Blood (1998) 0.94
Enhanced in vivo selection of bone marrow cells by retroviral-mediated coexpression of mutant O6-methylguanine-DNA-methyltransferase and HOXB4. Mol Ther (2004) 0.94
Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent. Proc Natl Acad Sci U S A (1996) 0.92
Protection and selection for gene therapy in the hematopoietic system. J Gene Med (2004) 0.91
Towards hematopoietic stem cell-mediated protection against infection with human immunodeficiency virus. Gene Ther (2006) 0.91
Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and secondary recipients. Mol Ther (2003) 0.90
Murine leukemia induced by retroviral gene marking. Science (2002) 3.59
Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science (2005) 3.58
Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood (2006) 3.07
Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther (2008) 2.56
Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther (2009) 2.56
Resistance of mature T cells to oncogene transformation. Blood (2008) 2.32
Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways. Blood (2006) 1.98
Lentiviral vectors pseudotyped with murine ecotropic envelope: increased biosafety and convenience in preclinical research. Exp Hematol (2006) 1.95
Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood (2005) 1.82
Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol Ther (2005) 1.82
Lentiviral vector design and imaging approaches to visualize the early stages of cellular reprogramming. Mol Ther (2011) 1.69
HOXB4 enforces equivalent fates of ES-cell-derived and adult hematopoietic cells. Proc Natl Acad Sci U S A (2005) 1.65
Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. Nat Med (2012) 1.58
Gene therapy: X-SCID transgene leukaemogenicity. Nature (2006) 1.57
Hepatic lentiviral gene transfer is associated with clonal selection, but not with tumor formation in serially transplanted rodents. Hepatology (2013) 1.55
LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia. Nat Med (2006) 1.52
Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region. Mol Ther (2009) 1.46
Upstream conserved sequences of mouse leukemia viruses are important for high transgene expression in lymphoid and hematopoietic cells. Mol Ther (2002) 1.44
Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther (2007) 1.44
Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol Ther (2008) 1.44
Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol (2004) 1.43
Retroviral vectors for high-level transgene expression in T lymphocytes. Hum Gene Ther (2003) 1.43
Medicine. Gene therapy--new challenges ahead. Science (2003) 1.43
HOXB4's road map to stem cell expansion. Proc Natl Acad Sci U S A (2007) 1.43
Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. Mol Ther (2007) 1.42
A modified γ-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med (2014) 1.42
Transcriptional enhancers induce insertional gene deregulation independently from the vector type and design. Mol Ther (2009) 1.39
MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood (2007) 1.37
Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood (2003) 1.34
Protein transduction from retroviral Gag precursors. Proc Natl Acad Sci U S A (2010) 1.30
Mice with ribosomal protein S19 deficiency develop bone marrow failure and symptoms like patients with Diamond-Blackfan anemia. Blood (2011) 1.28
Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis. Mol Ther (2009) 1.21
Predictable and efficient retroviral gene transfer into murine bone marrow repopulating cells using a defined vector dose. Exp Hematol (2003) 1.16
Tumor cells escape suicide gene therapy by genetic and epigenetic instability. Blood (2004) 1.11
Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice. PLoS Pathog (2013) 1.08
Clinical application of lentiviral vectors - concepts and practice. Curr Gene Ther (2008) 1.07
Ectopic HOXB4 overcomes the inhibitory effect of tumor necrosis factor-{alpha} on Fanconi anemia hematopoietic stem and progenitor cells. Blood (2009) 1.07
Unmodified Cre recombinase crosses the membrane. Nucleic Acids Res (2002) 1.04
Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapy. Mol Ther (2011) 1.04
Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy. Mol Pharm (2011) 1.03
Retroviral pseudotransduction for targeted cell manipulation. Mol Cell (2004) 1.02
Lentiviral vector induced insertional haploinsufficiency of Ebf1 causes murine leukemia. Mol Ther (2012) 1.01
Biosafety features of lentiviral vectors. Hum Gene Ther (2013) 1.01
Multiplexing RMCE: versatile extensions of the Flp-recombinase-mediated cassette-exchange technology. J Mol Biol (2010) 1.00
Self-inactivating alpharetroviral vectors with a split-packaging design. J Virol (2010) 1.00
Sleeping Beauty transposon-based system for cellular reprogramming and targeted gene insertion in induced pluripotent stem cells. Nucleic Acids Res (2012) 0.98
Stem cell marking with promotor-deprived self-inactivating retroviral vectors does not lead to induced clonal imbalance. Mol Ther (2008) 0.98
Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy. Mol Ther (2012) 0.98
Alpharetroviral self-inactivating vectors: long-term transgene expression in murine hematopoietic cells and low genotoxicity. Mol Ther (2012) 0.98
Retroviral integration site analysis in hematopoietic stem cells. Methods Mol Biol (2008) 0.97
Polyclonal fluctuation of lentiviral vector-transduced and expanded murine hematopoietic stem cells. Blood (2011) 0.97
Retroviral and transposon-based tet-regulated all-in-one vectors with reduced background expression and improved dynamic range. Hum Gene Ther (2010) 0.97
Avoiding cytotoxicity of transposases by dose-controlled mRNA delivery. Nucleic Acids Res (2011) 0.96
Preventing and exploiting the oncogenic potential of integrating gene vectors. J Clin Invest (2009) 0.95
Evaluating a ligation-mediated PCR and pyrosequencing method for the detection of clonal contribution in polyclonal retrovirally transduced samples. Hum Gene Ther Methods (2013) 0.95
Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trials. Mol Ther (2007) 0.94
The genomic risk of somatic gene therapy. Semin Cancer Biol (2010) 0.93
Viral and non-viral approaches for transient delivery of mRNA and proteins. Curr Gene Ther (2011) 0.93
Benefits of utilizing gene-modified iPSCs for clinical applications. Cell Stem Cell (2010) 0.92
Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells. Cancer Res (2008) 0.92
Generation and genetic modification of induced pluripotent stem cells. Expert Opin Biol Ther (2010) 0.91
Genetic modification of lymphocytes by retrovirus-based vectors. Curr Opin Immunol (2012) 0.91
Gammaretroviral vectors: biology, technology and application. Viruses (2011) 0.91
HOXB4 inhibits cell growth in a dose-dependent manner and sensitizes cells towards extrinsic cues. Cell Cycle (2006) 0.90
Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning. Mol Ther (2011) 0.88
The cytotoxic effect of mistletoe lectins I, II and III on sensitive and multidrug resistant human colon cancer cell lines in vitro. Toxicology (2002) 0.88
In vivo analysis of retroviral enhancer mutations in hematopoietic cells: SP1/EGR1 and ETS/GATA motifs contribute to long terminal repeat specificity. J Virol (2002) 0.88
Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing. Mol Ther (2012) 0.88
Overexpression of MDR1 using a retroviral vector differentially regulates genes involved in detoxification and apoptosis and confers radioprotection. Radiat Res (2006) 0.88
Efficient hematopoietic redifferentiation of induced pluripotent stem cells derived from primitive murine bone marrow cells. Stem Cells Dev (2011) 0.88
Transatlantic consortium spotlights need for changes in gene therapy trials. Mol Ther (2010) 0.87
Lenti in red: progress in gene therapy for human hemoglobinopathies. J Clin Invest (2004) 0.87
Design and production of retro- and lentiviral vectors for gene expression in hematopoietic cells. Methods Mol Biol (2009) 0.86
Lentiviral gene transfer regenerates hematopoietic stem cells in a mouse model for Mpl-deficient aplastic anemia. Blood (2011) 0.86
Cellular restriction of retrovirus particle-mediated mRNA transfer. J Virol (2008) 0.85
Murine leukemia virus regulates alternative splicing through sequences upstream of the 5' splice site. J Biol Chem (2006) 0.85
Protein scaffold and expression level determine antiviral activity of membrane-anchored antiviral peptides. Hum Gene Ther (2009) 0.85
Deletion of the LTR enhancer/promoter has no impact on the integration profile of MLV vectors in human hematopoietic progenitors. PLoS One (2013) 0.84
Role of the Multidrug Resistance Protein 1 in protection from heavy metal oxyanions: investigations in vitro and in MRP1-deficient mice. Biochem Biophys Res Commun (2002) 0.84
High-affinity neurotrophin receptors and ligands promote leukemogenesis. Blood (2008) 0.84
What are the consequences of the fourth case? Mol Ther (2007) 0.84
From bench to bedside: preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease. Hum Gene Ther Clin Dev (2013) 0.84
Solving the problem of γ-retroviral vectors containing long terminal repeats. Mol Ther (2011) 0.84
Multidrug resistance 1 gene transfer can confer chemoprotection to human peripheral blood progenitor cells engrafted in immunodeficient mice. Hum Gene Ther (2002) 0.83
Limited complementarity between U1 snRNA and a retroviral 5' splice site permits its attenuation via RNA secondary structure. Nucleic Acids Res (2009) 0.83
Engineered long terminal repeats of retroviral vectors enhance transgene expression in hepatocytes in vitro and in vivo. Mol Ther (2003) 0.81
Pseudotype-independent nonspecific uptake of gammaretroviral and lentiviral particles in human cells. Hum Gene Ther (2012) 0.81
Retroviral protein transfer: falling apart to make an impact. Curr Gene Ther (2012) 0.81
Gene therapy of MPL deficiency: challenging balance between leukemia and pancytopenia. Mol Ther (2009) 0.80
CD34 modulates the trafficking behavior of hematopoietic cells in vivo. Stem Cells Dev (2007) 0.80
Insertional mutagenesis by replication-deficient retroviral vectors encoding the large T oncogene. Ann N Y Acad Sci (2007) 0.80
Gene therapy for inherited disorders of haematopoietic cells. Hematol J (2004) 0.79
Angptl4 maintains in vivo repopulation capacity of CD34+ human cord blood cells. Eur J Haematol (2012) 0.79
Expression of the p75 neurotrophin receptor in acute leukaemia. Br J Haematol (2005) 0.79
Control of self-renewal and differentiation of hematopoietic stem cells: HOXB4 on the threshold. Ann N Y Acad Sci (2005) 0.79
Gene therapy needs both trials and new strategies. Nature (2004) 0.78
Gamma-glutamylcysteine synthetase and L-buthionine-(S,R)-sulfoximine: a new selection strategy for gene-transduced neural and hematopoietic stem/progenitor cells. Hum Gene Ther (2005) 0.78
Histone methyltransferase Suv39h1 deficiency prevents Myc-induced chromosomal instability in murine myeloid leukemias. Genes Chromosomes Cancer (2013) 0.78
Simplified generation of high-titer retrovirus producer cells for clinically relevant retroviral vectors by reversible inclusion of a lox-P-flanked marker gene. Mol Ther (2004) 0.78